BTIG downgraded Verona Pharma (VRNA) to Neutral from Buy without a price target after Merck (MRK) announced it will acquire Verona for $10B or $107 per share.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma downgraded to Equal Weight from Overweight at Wells Fargo
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Verona Pharma downgraded to Hold from Buy at TD Cowen
- Merck’s Acquisition of Verona Pharma Caps Stock’s Upside Potential, Downgraded to Hold
- Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz